Chronic use of steroids in premature infants has been associated with which condition?

Prepare for the ASPEN Certified Nutrition Support Clinician (CNSC) Exam. Study with structured quizzes and detailed insights to enhance your knowledge and readiness. Get set for success!

Multiple Choice

Chronic use of steroids in premature infants has been associated with which condition?

Explanation:
Chronic exposure to glucocorticoids in premature infants primarily disrupts bone mineralization. Steroids inhibit osteoblast activity and promote osteoclast survival, decrease intestinal calcium absorption, and increase renal calcium excretion, all of which shift the balance toward bone loss. In the already vulnerable bones of preterm babies, this leads to osteopenia and a higher risk of fractures. Cholestasis, nephrolithiasis, and hypoglycemia are less directly linked to chronic steroid exposure in this context. Cholestasis in premature infants is more commonly related to liver dysfunction or parenteral nutrition, not a typical consequence of steroids. Nephrolithiasis isn’t a classic consequence of prolonged glucocorticoids in this population, and steroids more often cause hyperglycemia rather than hypoglycemia.

Chronic exposure to glucocorticoids in premature infants primarily disrupts bone mineralization. Steroids inhibit osteoblast activity and promote osteoclast survival, decrease intestinal calcium absorption, and increase renal calcium excretion, all of which shift the balance toward bone loss. In the already vulnerable bones of preterm babies, this leads to osteopenia and a higher risk of fractures.

Cholestasis, nephrolithiasis, and hypoglycemia are less directly linked to chronic steroid exposure in this context. Cholestasis in premature infants is more commonly related to liver dysfunction or parenteral nutrition, not a typical consequence of steroids. Nephrolithiasis isn’t a classic consequence of prolonged glucocorticoids in this population, and steroids more often cause hyperglycemia rather than hypoglycemia.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy